Babies can be safely administered antibody protection against respiratory syncytial virus after birth even if their moms had ...
The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
By Dennis Thompson HealthDay ReporterMONDAY, Oct. 20, 2025 (HealthDay News) — Babies can be safely administered antibody ...
The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...
Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy ...
A Long Island woman had no idea what had hit her. Her pursuit of an answer led to a mosquito-borne disease rarely seen in the ...
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...
Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.
Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.